NewCardio, Inc. (NWCI)
0.0001
0.00 (0.00%)
USD |
OTCM |
Dec 11, 14:09
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0033M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 9.90K% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.99% |
Profile
| NewCardio, Inc. is a cardiac diagnostic technology provider, which focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular diseases, as well as the cardiac safety assessment of drugs under development. It engages in the development of three solutions through a 3D platform technology, which includes, QTinno, an automated cardiac safety solution that streamlines the process for meeting the early phase cardiac safety analysis, CardioBip, a wireless transtelephonic system which engages in delivering remote diagnosis and review of patients with chronic cardiac conditions, and my3KG, a software application developed to assess cardiac electrical activity in time and space. The company was founded on September 2, 2003 and is headquartered in Princeton, NJ. |
| URL | N/A |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Technology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| NewCardio, Inc. is a cardiac diagnostic technology provider, which focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular diseases, as well as the cardiac safety assessment of drugs under development. It engages in the development of three solutions through a 3D platform technology, which includes, QTinno, an automated cardiac safety solution that streamlines the process for meeting the early phase cardiac safety analysis, CardioBip, a wireless transtelephonic system which engages in delivering remote diagnosis and review of patients with chronic cardiac conditions, and my3KG, a software application developed to assess cardiac electrical activity in time and space. The company was founded on September 2, 2003 and is headquartered in Princeton, NJ. |
| URL | N/A |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Technology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |